Compare Amgen, Inc. (AMGN) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Hyatt Hotels Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Hyatt Hotels Corporation trades at $190.5 (market cap $18.00B). The key difference: Amgen, Inc. is far larger — about 10.9× Hyatt Hotels Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | H | |
|---|---|---|
Market Cap | $196.12B | $18.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $202.09 |
52-Week Low | $271.18 | $135.01 |
Enterprise Value | $241.41B | $21.84B |
Dividend Yield | 2.77% | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Hyatt Hotels Corp (H) trades at $191.14, up 0.63% on the day, with a bearish technical signal but mixed earnings performance. Recent quarters show beats on EPS estimates, though net income margin remains negative at -0.48%. The company announced expansion plans, including a new Hyatt Regency in Tucson, amid stable revenue around $7.1B. Cash flow trends indicate operational challenges, with net cash flow turning negative in 2025.
Outlook is cautious with analyst consensus tilted toward Hold (52.08%). Upside exists if operational efficiency improves and travel demand sustains, but risks include high debt levels and profitability pressures. The stock trades near the consensus price target of $197.30, suggesting limited near-term upside without fundamental catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
